About PharmEnable Therapeutics

PharmEnable Therapeutics uses artificial intelligence to discover small molecule drugs for disease targets that conventional drug discovery methods cannot access. The company's proprietary chemSEEK platform unlocks vast chemical spaces to design novel therapeutics with the specificity of biologics in the powerful, scalable form of a small molecule, focusing primarily on oncology and central nervous system diseases. Spun out from groundbreaking research at the University of Cambridge, PharmEnable addresses the bottleneck in chemical diversity that limits traditional drug discovery. The company develops first in class and best in class medicines for challenging, data sparse targets where patients face unmet medical needs.